Silo Pharma Secures Canadian Patent for Lead PTSD Drug Candidate SPC-15

Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent application covering its lead asset, SPC-15, an intranasal 5-HT4 receptor agonist designed to treat post-traumatic stress disorder (PTSD) and other stress-induced psychiatric disorders. This development represents a significant milestone in the company's global intellectual property strategy, as it provides exclusive rights in Canada through a license agreement with Columbia University, which also covers further development, manufacturing, and commercialization worldwide.

The Canadian patent allowance follows a recently granted European patent covering the same core invention, and corresponding intellectual property is either granted or advancing in multiple international markets. This expanding patent portfolio is critical for Silo Pharma as it prepares to advance SPC-15 through clinical development and potential commercialization. The company plans to utilize the FDA's 505(b)(2) regulatory pathway, which could shorten clinical timelines and reduce development costs by relying on existing data for the active ingredient.

The importance of this patent allowance extends beyond mere legal protection. It validates the novelty and potential of SPC-15 as a therapeutic option for PTSD, a condition that affects millions worldwide and for which current treatments often have significant limitations. By securing patent protection in key markets, Silo Pharma is positioning itself to attract potential partners and investors, as the exclusivity provided by patents is a cornerstone of pharmaceutical value.

Dr. Eric Weisblum, Chief Executive Officer of Silo Pharma, emphasized the strategic significance of the Canadian patent, noting that it strengthens the company's ability to pursue its development plans and reinforces its commitment to addressing underserved psychiatric conditions. The company's pipeline also includes SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis, all developed in collaboration with leading academic institutions.

For investors, this news underscores Silo Pharma's progress in building a robust IP estate around its lead candidate. The use of the 505(b)(2) pathway could be a game-changer, potentially allowing for a more efficient and cost-effective path to market compared to traditional new drug applications. However, as with any developmental-stage biopharmaceutical company, significant risks remain, including clinical trial outcomes and regulatory approvals.

The Canadian patent allowance is a clear indicator of Silo Pharma's forward momentum. As the company continues to advance SPC-15, it will be essential to watch for upcoming clinical milestones and regulatory interactions. The global IP protection now in place provides a solid foundation for potential commercialization and partnership opportunities, making this a key development for the company and its shareholders.